Figure 5.

Infliximab (IFX) therapy induces clinical remission and promotes intestinal mucosal healing in CD patients. The levels of ESR (A), CRP (B), Alb (C), Hb (D), and SES-CD (E) were determined in IFX-treated patients with active CD before and after IFX treatment, as described in the Materials and Methods. **p<0.01 compared with those before IFX treatment. CD: Crohn’s disease, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, Alb: albumin, Hb: hemoglobin, SES-CD: simple endoscopic score for CD